
Andreas Wack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/108334/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Host-directed immunotherapy of viral and bacterial infections: past, present and future. Nature Reviews Immunology, 2023, 23, 121-133.	22.7	71
2	A family of conserved bacterial virulence factors dampens interferon responses by blocking calcium signaling. Cell, 2022, 185, 2354-2369.e17.	28.9	26
3	Monocyte and dendritic cell defects in COVID-19. Nature Cell Biology, 2021, 23, 445-447.	10.3	23
4	Selective Janus kinase inhibition preserves interferon-λ–mediated antiviral responses. Science Immunology, 2021, 6, .	11.9	16
5	Rotavirus susceptibility of antibiotic-treated mice ascribed to diminished expression of interleukin-22. PLoS ONE, 2021, 16, e0247738.	2.5	9
6	The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell, 2021, 184, 4953-4968.e16.	28.9	165
7	A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza. Journal of Experimental Medicine, 2021, 218, .	8.5	10
8	Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival. Journal of Experimental Medicine, 2021, 218, .	8.5	31
9	Influenza A induces lactate formation to inhibit type I IFN in primary human airway epithelium. IScience, 2021, 24, 103300.	4.1	10
10	Recruitment of dendritic cell progenitors to foci of influenza A virus infection sustains immunity. Science Immunology, 2021, 6, eabi9331.	11.9	14
11	Influenza-induced monocyte-derived alveolar macrophages confer prolonged antibacterial protection. Nature Immunology, 2020, 21, 145-157.	14.5	193
12	Tissue-specific and interferon-inducible expression of nonfunctional ACE2 through endogenous retroelement co-option. Nature Genetics, 2020, 52, 1294-1302.	21.4	82
13	COVID-19 and emerging viral infections: The case for interferon lambda. Journal of Experimental Medicine, 2020, 217, .	8.5	177
14	An ace model for SARS-CoV-2 infection. Journal of Experimental Medicine, 2020, 217, .	8.5	4
15	Teaching Old Dogs New Tricks? The Plasticity of Lung Alveolar Macrophage Subsets. Trends in Immunology, 2020, 41, 864-877.	6.8	51
16	Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science, 2020, 369, 712-717.	12.6	333
17	Transcriptional profiling unveils type I and II interferon networks in blood and tissues across diseases. Nature Communications, 2019, 10, 2887.	12.8	65
18	Microbiota-Driven Tonic Interferon Signals in Lung Stromal Cells Protect from Influenza Virus Infection. Cell Reports, 2019, 28, 245-256.e4.	6.4	208

ANDREAS WACK

#	Article	IF	CITATIONS
19	Monocytes work harder under pressure. Nature Immunology, 2019, 20, 1422-1424.	14.5	6
20	Multiple Levels of Control Determine How E4bp4/Nfil3 Regulates NK Cell Development. Journal of Immunology, 2018, 200, 1370-1381.	0.8	25
21	Interfering with transmission. ELife, 2018, 7, .	6.0	2
22	Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement. Nature Communications, 2017, 8, 14253.	12.8	33
23	<scp>IFN</scp> λ is a potent antiâ€influenza therapeutic without the inflammatory side effects of <scp>IFN</scp> α treatment. EMBO Molecular Medicine, 2016, 8, 1099-1112.	6.9	228
24	The aryl hydrocarbon receptor controls cyclin O to promote epithelial multiciliogenesis. Nature Communications, 2016, 7, 12652.	12.8	23
25	TRAIL ⁺ monocytes and monocyteâ€related cells cause lung damage and thereby increase susceptibility to influenza– <i> <scp>S</scp> treptococcus pneumoniae </i> coinfection. EMBO Reports, 2015, 16, 1203-1218.	4.5	82
26	A Serpin Shapes the Extracellular Environment to Prevent Influenza A Virus Maturation. Cell, 2015, 160, 631-643.	28.9	137
27	Type I interferons in infectious disease. Nature Reviews Immunology, 2015, 15, 87-103.	22.7	1,902
28	Guarding the frontiers: the biology of type III interferons. Nature Immunology, 2015, 16, 802-809.	14.5	279
29	Disease-Promoting Effects of Type I Interferons in Viral, Bacterial, and Coinfections. Journal of Interferon and Cytokine Research, 2015, 35, 252-264.	1.2	154
30	Stop the executioners. Nature Immunology, 2015, 16, 6-8.	14.5	1
31	The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression. Journal of Experimental Medicine, 2014, 211, 635-642.	8.5	168
32	The Transcription Factor E4BP4 Is Not Required for Extramedullary Pathways of NK Cell Development. Journal of Immunology, 2014, 192, 2677-2688.	0.8	51
33	Pathogenic potential of interferon $\hat{l}\pm\hat{l}^2$ in acute influenza infection. Nature Communications, 2014, 5, 3864.	12.8	315
34	Themis2 Is Not Required for B Cell Development, Activation, and Antibody Responses. Journal of Immunology, 2014, 193, 700-707.	0.8	12
35	Type I and Type III Interferons Drive Redundant Amplification Loops to Induce a Transcriptional Signature in Influenza-Infected Airway Epithelia. PLoS Pathogens, 2013, 9, e1003773.	4.7	229
36	Intranasal Administration of CpG Induces a Rapid and Transient Cytokine Response Followed by Dendritic and Natural Killer Cell Activation and Recruitment in the Mouse Lung. Journal of Innate Immunity, 2010, 2, 144-159.	3.8	26

2

#	Article	IF	CITATIONS
37	Multiple sites of post-activation CD8+ T cell disposal. European Journal of Immunology, 1997, 27, 577-583.	2.9	45

Anti-type I interferon antibodies as a cause of severe COVID-19., 0, 11, .